<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>AmitisGen TECH Dev Group</PublisherName>
				<JournalTitle>Personalized and Precision Medicine Journal</JournalTitle>
				<Issn>3115-7874</Issn>
				<Volume>10</Volume>
				<Issue>39</Issue>
				<PubDate PubStatus="epublish">
					<Year>2025</Year>
					<Month>12</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Managing Inflammation in Cancer Therapy: Effects of Inflammation Control on Metastasis and Treatment Response</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>43</FirstPage>
			<LastPage>53</LastPage>
			<ELocationID EIdType="pii">732230</ELocationID>
			
<ELocationID EIdType="doi">10.22034/ppmj.2025.2066236.1065</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Maryam</FirstName>
					<LastName>Abbasi Saeidi</LastName>
<Affiliation>Department of Biology, Faculty of Basic Sciences, Science &amp; Research Branch, Islamic Azad University, Tehran, Iran.</Affiliation>
<Identifier Source="ORCID">0009-0009-2418-8726</Identifier>

</Author>
<Author>
					<FirstName>Mina I</FirstName>
					<LastName>Ekrami Noghab</LastName>
<Affiliation>Department of Pediatrics, Bohlool Hospital, Gonabad University of Medical Sciences, Gonabad, Iran.</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2025</Year>
					<Month>07</Month>
					<Day>15</Day>
				</PubDate>
			</History>
		<Abstract>Chronic inflammation is a pivotal element in the onset and advancement of cancer. It is crucial in tumor initiation, survival, metastasis, and therapeutic resistance. This study seeks to thoroughly examine the intricate relationship between inflammation and cancer, emphasizing the role of inflammatory processes in tumor formation and their influence on cancer therapy responses. We will investigate the molecular processes behind inflammation-induced cancer progression, analyze how inflammation affects metastasis, and assess its effects on the effectiveness of treatments like chemotherapy, immunotherapy, and targeted therapies. Furthermore, we will investigate prospective therapeutic approaches for addressing inflammation in cancer treatment, emphasizing the necessity for specific modulation to enhance treatment efficacy while mitigating adverse consequences such as immune suppression or heightened infection risk. The report finishes with a discussion on prospective research avenues focused on optimizing inflammation-targeting techniques to augment the efficacy of cancer therapies and better patient outcomes. Ultimately, a deeper understanding of inflammation’s dual role in cancer could pave the way for innovative, more personalized treatment strategies that improve survival and quality of life for patients.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Inflammation</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Cancer progression</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">tumor microenvironment</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Metastasis</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Cytokines</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://www.pmjournal.ir/article_732230_aef0e346eb232069ec6e401bbd73f324.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
